Eli Lilly and Company (LLY) Receives Price Target

Eli Lilly and Company (LLY) : The consensus price target for Eli Lilly and Company (LLY) is $95.73 for the short term with a standard deviation of $17.14. The most optimist securities analyst among the 11 who monitor the stock believes that the stock can reach $116, however, the pessimist price target for the company is $55.

Eli Lilly and Company (LLY) : 13 analysts are covering Eli Lilly and Company (LLY) and their average rating on the stock is 1.77, which is read as a Buy. 9 equity analysts believe that the stock has a bright future and the price doesnt capture all of its upside, hence they rate the stock as a Strong Buy. A Zacks Investment Research rank of 3, which recommends a Hold affirms that they expect a large upside in the stock from the current levels. However, 1 analysts consider that the stock has more downward risks ahead, hence, they suggest a Strong Sell on the stock. A total of 3 brokerage firms believe that the stock is fairly valued, hence they advise a Hold on the stock.


Also, Argus Research maintains its rating on Eli Lilly and Company (NYSE:LLY). The global brokerage major raises the current price target from $90 per share to $95 per share. Analysts at the Argus Research have a current rating of Buy on the shares. The rating by the firm was issued on August 2, 2016.

Eli Lilly and Company (NYSE:LLY): The stock opened at $77.75 on Thursday but the bulls could not build on the opening and the stock topped out at $78.00 for the day. The stock traded down to $76.80 during the day, due to lack of any buying support eventually closed down at $77.23 with a loss of -0.67% for the day. The stock had closed at $77.75 on the previous day. The total traded volume was 3,544,701 shares.

Eli Lilly and Company (Lilly) is engaged in drug manufacturing business. The Company discovers, develops, manufactures and market products in two segments: human pharmaceutical products and animal health products. The Companys products are sold in approximately 120 countries. The Companys human pharmaceutical business segment sells medicines, which are discovered or developed by its scientists. Its animal health business segment operates through the Companys Elanco division, which develops, manufactures and markets products for both food animals and companion animals. The Company manufactures and distributes its products through facilities in the United States, Puerto Rico and 11 other countries. Its products include endocrinology products, neuroscience products, oncology products, cardiovascular products, products for food animals, products for companion animals and Novartis AH products.

Leave a Reply

Get Pre-Market Alerts!

Get Pre-Market Analysts' Upgrades, Downgrades, Earnings & Initiations with our FREE daily email newsletter.